Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Japanese Journal of Clinical Oncology

• Publication date

  1999-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JJCO/29.11.550PMID 10678558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

  1997cited by this paper
• The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract.

  1997cited by this paper
• Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.

  1997cited by this paper
• [Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C].

  1996cited by this paper
• The treatment of advanced gastric cancer.

  1996cited by this paper
• Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours.

  1995cited by this paper
• Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

  1995cited by this paper
• [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer].

  1994cited by this paper
• Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG).

  1994cited by this paper
• An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer.

  1993cited by this paper
• Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

  1993cited by this paper
• The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.

  1993cited by this paper
• Evaluation of seven tumor markers (CA 50, CA 19‐9, CA 19‐9 TruQuant, CA 72‐4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma

  1992cited by this paper
• [Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group].

  1987cited by this paper
• Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.

  1987cited by this paper
• Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients.

  1985cited by this paper
• Second‐look laparotomy based on CEA elevations in colorectal cancer

  1981cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper
• Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer.

  1978cited by this paper

• Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer

  2025cites this paper
• Trends in Colorectal Cancer Peritoneal Metastases Research: A Comprehensive Bibliometric Analysis

  2025cites this paper
• Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer

  2024cites this paper
• CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer

  2024cites this paper
• A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological–Oncological Diseases

  2023cites this paper
• DNA methylation drives a new path in gastric cancer early detection: Current impact and prospects

  2023cites this paper
• Deep learning predicts resistance to neoadjuvant chemotherapy for locally advanced gastric cancer: a multicenter study

  2022cites this paper
• A novel hematological classifier predicting chemotherapy benefit and recurrence hazard for locally advanced gastric cancer A multicenter IPTW analysis.

  2022cites this paper
• Primary and metastatic peritoneal surface malignancies

  2021cites this paper
• Combination of preoperative CA19-9 levels, cell differentiation, and age predicts survival for patients with gastric cancer before surgery

  2021cites this paper
• Prediction Model of Tumor Regression Grade for Advanced Gastric Cancer After Preoperative Chemotherapy

  2021influential citation
• Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei—A Novel Treatment Approach

  2020cites this paper
• An immunosensor for the determination of carcinoembryonic antigen by Surface Plasmon Resonance Imaging.

  2020cites this paper
• Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients With Gastric Cancer

  2019cites this paper
• Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.

  2019cites this paper
• Clinical significance of serum tumor markers for advanced gastric cancer with the first-line chemotherapy

  2019cites this paper
• Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing?

  2018cites this paper
• Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading

  2018cites this paper
• Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer

  2018cites this paper
• The clinical impact of the novel tumor marker DR‐70 in unresectable gastric cancer patients

  2018cites this paper
• EVALUATION OF CARCINO EMBRYONIC ANTIGEN (CEA) AND CARBOHYDRATE ANTIGEN (CA19-9) IN MONITORING OF TREATMENT RESPONSE IN GASTROINTESTINAL CANCERS

  2018cites this paper
• Prognostic Value of CEA and CA 19.9 in Gastric Cancer

  2017cites this paper
• The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice.

  2017cites this paper
• A new score for screening of malnutrition in patients with inoperable gastric adenocarcinoma

  2017cites this paper
• Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma

  2016cites this paper
• Clinical Significance of CA125 Level with Clinicopathological Variables and Peritoneal Dissemination in Patients with Gastric Carcinoma

  2016cites this paper
• Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer.

  2016cites this paper
• Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.

  2016cites this paper
• Tumor Marker for Diagnosis and Monitoring Response to chemotherapy for Oesophagus Cancer Patients

  2016cites this paper
• Proteomic analysis and translational perspective of hepatocellular carcinoma: Identification of diagnostic protein biomarkers by an onco‐proteogenomics approach

  2016cites this paper
• Use of Tumor Markers in Gastrointestinal Cancers: Surgeon Perceptions and Cost-Benefit Trade-Off Analysis

  2016cites this paper
• Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma

  2016cites this paper
• Marqueurs sériques

  2016cites this paper
• Matrix Metalloproteinases and Their Tissue Inhibitors in Comparison to Other Inflammatory Proteins in Gastric Cancer (GC)

  2016cites this paper
• Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.

  2015cites this paper
• GASTRIC CANCER TUMOR MARKERS

  2015cites this paper
• Changing patterns of Serum CEA and CA199 for Evaluating the Response to First-line Chemotherapy in Patients with Advanced Gastric Adenocarcinoma.

  2015influential citation
• Alpha-fetoprotein (AFP) elevation gastric adenocarcinoma and importance of AFP change in tumor response evaluation.

  2015cites this paper
• Evaluation of some tumor markers, acute phase proteins, sialic acid and lipid bound sialic acid before and after chemotherapy in stomach cancer

  2015cites this paper
• Decreased expression of Bauhinia purpurea lectin is a predictor of gastric cancer recurrence

  2015cites this paper
• Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis: symptom/tumor marker-based versus CT-based.

  2014cites this paper
• Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy

  2014influential citation
• Prognostic value of carbohydrate tumor markers and inflammation-based markers in metastatic or recurrent gastric cancer

  2014cites this paper
• Clinical significance of EBP50 overexpression assessed by quantum dot analysis in gastric cancer

  2013influential citation
• Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy

  2013cites this paper
• Serum CA 19‐9 as a prognostic factor in patients with metastatic gastric cancer

  2013cites this paper
• Clinical and Experimental Studies in Peritoneal Metastases from Gastric Cancer

  2013cites this paper
• Clinical Assessment and Prognostic Evaluation of Tumor Markers in Patients with Gastric Cancer

  2013cites this paper
• Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

  2013influential citation
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 886 Clinical and Experimental Studies in Peritoneal Metastases from Gastric Cancer

  2013cites this paper
• Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis)

  2013influential citation
• Effect of acrylamide on some hormones and endocrine tissues in male rats

  2012cites this paper
• Carcinoembryonic antigen; lack of clinical utility in a case of metastatic colorectal carcinoma

  2012cites this paper
• Cancer Pain Managment with a Venom of Blue Scorpion Endemic in Cuba, Called Rhopalurus Junceus " Escozul"

  2012cites this paper
• Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients.

  2012cites this paper
• Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination

  2012cites this paper
• Titration of serum CEA , sFasL , CEA-IgM complexes and sFasL-IgM complexes in patients with gastric adenocarcinoma

  2011cites this paper
• Guías de práctica de laboratorio clínico Uso de los marcadores tumorales en el cáncer de hígado, de vejiga, cervical y gástrico: Capítulos 4 y 5

  2011cites this paper
• National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.

  2010cites this paper
• MELATONIN, CORTISOL, PROLACTIN AND IGA LEVELS AND THEIR IMPLICATION ON CIRCADIAN-BASED CANCER THEORY

  2010cites this paper
• Laboratory Medicine Practice Guidelines Use of Tumor Markers in Liver , Bladder , Cervical , and Gastric Cancers

  2010cites this paper
• Detection of circulating CEA-IgM complexes in early stage gastric cancer

  2010cites this paper
• Utilidad clínica de los marcadores tumorales

  2010cites this paper
• The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites

  2010cites this paper
• Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.

  2009cites this paper
• Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer

  2009cites this paper
• Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer.

  2008cites this paper
• Unusually high serum CA19.9 in gastric carcinoma: A case report

  2008cites this paper
• Carcinoembryonic Antigen in Monitoring of Response to Cetuximab plus FOLFIRI or FOLFOX-4 in Patients with Metastatic Colorectal Cancer

  2008cites this paper
• Prognostic significance of serum and tissue carcinoembryonic antigen in patients with gastric adenocarcinomas.

  2008cites this paper
• The significance of serum transforming growth factor beta 1 in detecting of gastric and colon cancers.

  2007cites this paper
• A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer

  2007influential citation
• Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors

  2007cites this paper
• Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors

  2007cites this paper
• A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer

  2006cites this paper
• A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer

  2006cites this paper
• The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study

  2003cites this paper
• CPT-11 and Cisplatin in the Treatment of Advanced Gastric Cancer in Asians

  2003cites this paper
• Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer.

  2002cites this paper
• Usefulness of Serum Carbohydrate Antigen 19-9 in Surgical Management of Mass-forming Intrahepatic Cholangiocarcinoma

  2002cites this paper
• Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer.

  2002cites this paper
• Isolation of Native Human Monoclonal Autoantibodies to Breast Cancer

  2002cites this paper
• Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer

  2001cites this paper
• Tumor markers in monitoring response to chemotherapy for patients with gastric cancer.

  1999cites this paper
• Preoperative Serum Tumor Marker Levels in Gastric Cancer

  1969cites this paper
• SERUM LEVELS OF IMMUNOGLOBULINS, TUMOUR MARKERS, AND CHEMOKINES IN GASTRIC CANCER PATIENTS TREATED WITH SOX REGIMEN VERSUS OXALIPLATIN MONOTHERAPY

  year unknowncites this paper
• National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Gastric Cancer

  year unknowncites this paper